Related references
Note: Only part of the references are listed.Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade
Sauri Hernandez-Resendiz et al.
BASIC RESEARCH IN CARDIOLOGY (2015)
Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix
Emma Robinson et al.
BASIC RESEARCH IN CARDIOLOGY (2015)
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes
Mitchel Tate et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Dipeptidyl Peptidase-4 Inhibitor Decreases Abdominal Aortic Aneurysm Formation through GLP-1-Dependent Monocytic Activity in Mice
Hsin Ying Lu et al.
PLOS ONE (2015)
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
Megan DeNicola et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
BMP-7 attenuates adverse cardiac remodeling mediated through M2 macrophages in prediabetic cardiomyopathy
Princess Urbina et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2014)
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
Andrew E. Hogan et al.
DIABETOLOGIA (2014)
Molecular mechanisms of diabetic cardiomyopathy
Heiko Bugger et al.
DIABETOLOGIA (2014)
Cardiovascular remodelling in coronary artery disease and heart failure
Gerd Heusch et al.
LANCET (2014)
Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection
John R. Ussher et al.
MOLECULAR METABOLISM (2014)
Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
Steven P. Moberly et al.
BASIC RESEARCH IN CARDIOLOGY (2013)
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
Derek J. Hausenloy et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Macrophages modulate cardiac function in lipotoxic cardiomyopathy
Joel D. Schilling et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2012)
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Daisuke Shiraishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
Y. -S. Lee et al.
DIABETOLOGIA (2012)
Exenatide Exerts a Potent Antiinflammatory Effect
Ajay Chaudhuri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice
Junichi Matsubara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Macrophage-Stimulated Cardiac Fibroblast Production of IL-6 Is Essential for TGF β/Smad Activation and Cardiac Fibrosis Induced by Angiotensin II
Feifei Ma et al.
PLOS ONE (2012)
Diabetic Cardiomyopathy Bench to Bedside
Joel D. Schilling et al.
HEART FAILURE CLINICS (2012)
Angptl4 deficiency decreases serum triglyceride levels in low-density lipoprotein receptor knockout mice and streptozotocin-induced diabetic mice
Hironori Adachi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
Youyou Zhao et al.
CANCER RESEARCH (2010)
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
Que Liu et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Vitamin B1 Analog Benfotiamine Prevents Diabetes-Induced Diastolic Dysfunction and Heart Failure Through Akt/Pim-1-Mediated Survival Pathway
Rajesh G. Katare et al.
CIRCULATION-HEART FAILURE (2010)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
Insulin-dependent Diabetes Mellitus in Mice Does Not Alter Liver Heparan Sulfate
Joseph R. Bishop et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study
Giovanni de Simone et al.
JOURNAL OF HYPERTENSION (2010)
Macrophages: Master Regulators of Inflammation and Fibrosis
Thomas A. Wynn et al.
SEMINARS IN LIVER DISEASE (2010)
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
David J. Grieve et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Adult human β-cell neogenesis?
C. Demeterco et al.
DIABETES OBESITY & METABOLISM (2009)
Myocardial overexpression of adenine nucleotide translocase 1 ameliorates diabetic cardiomyopathy in mice
Yong Wang et al.
EXPERIMENTAL PHYSIOLOGY (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Mechanisms of Cardiac Fibrosis in Inflammatory Heart Disease
Gabriela Kania et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2009)
Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat
Indu Poornima et al.
CIRCULATION-HEART FAILURE (2008)
Exploring the full spectrum of macrophage activation
David M. Mosser et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy -: The role of angiotensin type 1 receptor antagonism
Dirk Westermann et al.
DIABETES (2007)
Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice
OJ How et al.
DIABETES (2006)
Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease
MR Movahed et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging
P Bonito et al.
DIABETIC MEDICINE (2005)
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model
AK Bose et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Mouse models of diabetic nephropathy
MD Breyer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
AG Bertoni et al.
DIABETES CARE (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Leptin as an adjunct of insulin therapy in insulin-deficient diabetes
F Miyanaga et al.
DIABETOLOGIA (2003)
Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice
LA Barouch et al.
CIRCULATION (2003)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice
LM Semeniuk et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Share Paper
